Navigation Links
Quest Diagnostics Reports Strong Performance in Second Quarter 2009
Date:7/21/2009

ased on the strong performance in the first half, we are raising earnings guidance for the full year."

For the second quarter, operating income increased to $359 million, or 18.9% of revenues, and included the $15.5 million insurance recovery. Operating income was $308 million, or 16.8% of revenues, for the second quarter of 2008.

For the second quarter of 2009, bad debt expense as a percentage of revenues was 4.4%, compared to 4.5% in the first quarter and unchanged from the prior year. Days sales outstanding improved to 43 days, compared to 46 days at the end of the second quarter of 2008 and 44 days at the end of last year. Cash flow used in operations, which reflects the $308 million payment related to the previously announced NID settlement, was $9 million. In the second quarter of 2008, cash provided by operations was $213 million. During the quarter, the company made capital expenditures of $36 million.

First Half Performance

For the first six months of 2009, income from continuing operations increased to $357 million, or $1.89 per diluted share, from $303 million, or $1.54 per diluted share for the first half of 2008. Revenues increased 2.4% to $3.7 billion.

Operating income for the first half of 2009 increased to $680 million, or 18.3% of revenues, compared to $588 million, or 16.2% of revenues for 2008. Cash provided by operations, which was reduced by $308 million related to the payment of the NID settlement, was $264 million compared to $371 million for 2008. During the first half of 2009, the company repurchased $250 million of its common shares, and made capital expenditures of $76 million.

Outlook for 2009

For 2009, the company today increased its estimated earnings per diluted share from continuing operations to between $3.70 and $3.80. Previously, the company estimated diluted earnings per share of between $3
'/>"/>

SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
2. The 7 Key Questions About the Schwarzenegger/Nunez Health Care Compromise
3. LifeQuest Announces End of Immunity Health Challenge Contest
4. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
5. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
6. Study Questions Dead-End Cancer Clinical Trials
7. 6 Years Later, 9/11 Health Questions Linger
8. U.S. Physicians Question Presidential Candidates
9. RFID Implant Cancer Questions Concern Patients
10. Study Questions Genetic Screening for Treatable Diseases
11. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Smart Balance, Inc. (Nasdaq: SMBL ... authorized a two-year stock repurchase program of up to ... program demonstrates the confidence we have in the prospects ... long-term value for all of our shareholders, while at ... Stephen Hughes, Smart Balance, Inc. Chairman and Chief Executive ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that Paul D. Mintz, M.D. has ... director, effective January 1, 2010. ,, Dr. Mintz ... for more than 30 years. He is a tenured ... Virginia School of Medicine. He also serves as director ...
(Date:12/16/2009)... 16 As a result of C3: Colorectal ... peer reviewed cancer research program is included in the ... This new cancer research program will research cancers, like ... prostate, lung and ovarian cancer research programs run by ... ,, The $15 million in funding for this ...
(Date:12/16/2009)... teams led by the Wellcome Trust Sanger Institute announce ... All cancers are caused by mutations in the DNA ... lifetime. The studies, of a malignant melanoma and a ... the mutations in the genomes of two cancers. , ... year: almost all are associated with smoking. The number ...
(Date:12/16/2009)... Access to Quality, Cost-Effective Care , ... Washington, D.C. ... debated the best ways to rein in runaway costs while providing ... important part of the ongoing discussion includes how to ensure patients ... doctors of medicine (MDs) or osteopathy (DOs). In both the ...
Breaking Medicine News(10 mins):Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:Immucor Appoints New Board Director 2Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5
... reason why smoking is bad for health. ,It seems that ... that protects against heart disease in their blood. The discovery ... risk of heart attacks than non-smokers. ,Paraoxonase is ... and blocking the blood vessels. A team of Swiss researchers ...
... old age appears to be linked to intellectual impairment over ... the Institute of Psychiatry in London carried out a community ... than 630 people aged 65 and over. Smoking and drinking ... volunteers' intellectual powers were also assessed. After excluding those who ...
... analysis, it is better to give radiation therapy before surgery ... as surgery can reduce the risk of recurrence. Generally the ... Scandinavia and the Netherlands, the therapy is given before surgery ... afterwards.// ,An analysis of 8000 patients, led by ...
... The fear of biological weapons such as anthrax may be ... experts. Long-term social or psychological damage could be the result ... letter to the British Medical Journal from researchers in the ... not kill many people, for many more, their prospect is ...
... five times more likely to die at birth than those ... carried out by doctors in the north-west of England also ... more likely to have babies with birth defects. ,The ... that babies born to women with diabetes in Swden were ...
... who are most at risk from high blood pressure have ... being neglected. Doctors are often reluctant to treat people with ... high cholesterol or diabetes. Maybe they believe little can be ... or they may worry about lowering blood pressure in a ...
Other Medicine News:Health News:All the more bad, 2
(Date:12/16/2009)... Dec. 16 /PRNewswire/ -- Sanofi ... Group, announced today that it has entered ... Syntiron to develop and commercialize its prophylactic ... Staphylococcus aureus or MRSA. MRSA ... humans, sometimes referred to as multidrug-resistant ...
(Date:12/16/2009)... N.Y., Dec. 16 BioSpecifics Technologies Corp. ... first in class collagenase-based products, today announced top-line ... clinical trial of XIAFLEX(TM) for the treatment of ... presence of inelastic collagen on the shaft of ... make sexual intercourse difficult or impossible in advanced ...
(Date:12/16/2009)... -- CVS/pharmacy and MinuteClinic health care centers located ... vaccine in 20 states and Washington, D.C. ... H1N1 vaccines continue, many states have lifted restrictions, ... the shot while supplies last. In addition, ... available at MinuteClinic locations across the country on ...
Breaking Medicine Technology:Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4Hardship in Childhood May Affect Long Term Health 63195 1Hardship in Childhood May Affect Long Term Health 63195 2Newly identified enzymes help plants sense elevated CO2 and could lead to water wise crops 11131 1Newly identified enzymes help plants sense elevated CO2 and could lead to water wise crops 11131 2Newly identified enzymes help plants sense elevated CO2 and could lead to water wise crops 11131 3Scientists use nanosensors for first time to measure cancer biomarkers in blood 11129 1Scientists use nanosensors for first time to measure cancer biomarkers in blood 11129 2
... the 2008 International Conference of the American ... ... Forest Laboratories, Inc. and,Laboratorios Almirall, S.A. today presented results ... bromide, an,investigational treatment for chronic obstructive pulmonary disease (COPD).,Data from ...
... Synta,Pharmaceuticals Corp. (Nasdaq: SNTA ) today ... (formerly STA-4783), an investigational agent,currently in development ... stage IV metastatic melanoma patients treated with ... chemotherapy had a,statistically significant improvement in progression-free ...
Other Medicine Technology:Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 2Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 3Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 4Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 2Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 3Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 4Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 5Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 6Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma 7
... use of guaiac as a test for the ... of phenolic compounds present in guaiac to quinones, ... If blood is present, the heme portion of ... manner, catalyzing the release of oxygen from hydrogen ...
... SENSA elitewas designed to improve patient compliance. ... and sample collection options make this fecal ... understand and complete. Diet guidelines are explained ... determine which foods and drugs are okay ...
... The Original MaybeMom™ Mini ... medical diagnostic instument which uses ... her personal menstrual/fertility cycle, including ... ovulation and menstruation to increase ...
... supporting the effectiveness and accuracy of the ... clinical studies. As a woman nears ovulation ... increases, thereby, elevating the salt in her ... is allowed to dry, crystalization occurs. The ...
Medicine Products: